林郑:政府与两疫苗制造商订协议分别供应750万剂 首批最快1月到港
行政长官林郑月娥出席记者会时表示,政府在疫苗采购方面有突破性发展,一方面香港已参加世卫的疫苗获取机制,已缴付按金获取总人口三成半的疫苗剂量,另外亦有洽谈并寻求与个别疫苗制造商签署预先采购协议,为全港人口免费接种疫苗,采购目标是起码买到两款来自不同制造商及不同疫苗技术平台的疫苗,即是采购量是全港人口的两倍,如疫苗需要接种两剂,即是最高采购剂量达到3,000万剂。
她指出现时已与两家疫苗制商商达成协议,当中科兴控股生物技术(SYNOVEX)会供应750万剂,首批100万剂可望最快明年1月来港,另一制造商是复星医药(02196.HK)、德国BioNTech及辉瑞药厂,将供应750万剂,首批最快明年首季来港。而另外第三间在谈、即将达成协议的是阿斯利康,可供应750万剂,最快到明年下半年到港。她指出会安排优先群组进行接种,包括是医护及长者等,期望明年内为大部分香港市民提供免费接种疫苗,并尽快恢复出行、商业活动等。
林郑指出,香港自11月下旬开始有新一波疫情,至今情况令人非常担忧,而且今次是因本地个案不断增加所带动,而本地个案中未有源头的个案比例持续上升,相关比例亦於最近一周达到逾三成,每宗源头不明本地个案都反映社区有隐形传播链,带来更大风险,故社交距离措施要更严格,发挥切断传播链的作用。她强调对疫苗采购工作从来无掉以轻心,并有严谨认真跟进采购工作,不过当中涉科学评估、采购亦涉商业协议,难公开透明每个阶段与大家分享采购工作进程。(el/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.